NSF award 2537614 · Rumedical Nova Limited Liability CO

SBIR Phase I: Next-Gen Portable Bio-Chip for Rapid and Accurate Early Lung Cancer Diagnosis

Final report due

29 April 2028

in 559 days · The award ends on 31 December 2027.

GrantClerk is a private service. We are not NSF or any government agency.

Dates this award owes

NSF emails you about this too.

Decide about an extension2 Sep 2027in 319 days
award ending 2027-12-31 · Research.gov
This one is ours, not NSF’s.
Extension request16 Nov 2027in 394 days
award ending 2027-12-31 · Research.gov
PAPPG 24-1: “at least 45 days prior to the end date”
No-cost extension notice21 Dec 2027in 429 days
award ending 2027-12-31 · Research.gov
PAPPG 24-1: “at least ten calendar days prior to the end date”
Final report due29 Apr 2028in 559 days
award ending 2027-12-31 · Research.gov
PAPPG 24-1: “no later than 120-days following the end date of the award”
Project outcomes report due29 Apr 2028in 559 days
award ending 2027-12-31 · Research.gov
PAPPG 24-1: “no later than 120 days following the end date”
Award is closed out29 Apr 2028in 559 days
award ending 2027-12-31 · Research.gov
PAPPG 24-1: “financially closed out 120 days after their expiration date”

Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.

How we got this date

NSF lists this award's end date as 31 December 2027.
NSF rules say the final report is due no later than 120 days after that.
So the final report is due by 29 April 2028.

Read the rule on Research.gov

Get a note before each report date

Add this award to your desk. We email you before each date and keep the dates in one place.

Renews each year until you cancel. Cancel any time from your account.

Already a member? Sign in

Award card

Award number: 2537614
Period of support: 15 Jul 2026 – 31 Dec 2027
Amount: $305,000
Awardee: Rumedical Nova Limited Liability CO, Austin, TX
Program: SBIR Phase I
Directorate: TIP

Abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in creating an affordable, portable, easy-use technology that can diagnose lung cancer at its earliest stages, when treatment is most effective. Lung cancer remains the leading cause of cancer-related deaths, largely because it has minimum symptoms until it reaches a late stage. By enabling early and…

Is this right?

We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.